Junshi Bio (688180.SH) announced on June 25 that the company has received a drug registration certificate issued by the National Medical Products Administration for JS001 (trade name: Tyvyt, product code: JS001), a monoclonal antibody, in combination with Nab-paclitaxel for the first-line treatment of recurrent or metastatic triple-negative breast cancer (TNBC) with fully validated detection and evaluation of PD-L1 positive (CPS≥1). This is the tenth approved indication of JS001 in mainland China.
君实生物(688180.SH)：特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获得批准
Junshi Biosciences (688180.SH): New indication for teriparitide monoclonal antibody for first-line treatment of advanced triple-negative breast cancer approved for marketing application.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.